TABLE 2.
Pathogen characteristics stratified by 30-day in-hospital mortalitya
| Characteristic | No. (%) of admissions with characteristic |
P value | ||
|---|---|---|---|---|
| Nonsurvivors (n = 109 [13.4% of admissions]) | Survivors (n = 705 [86.6% of admissions]) | All admissions (n = 814) | ||
| agr dysfunction | 33 (30.3) | 149 (21.0) | 182 (22.2) | 0.03 |
| Methicillin resistance | 70 (64.2) | 418 (59.3) | 488 (60.0) | 0.33 |
| hVISA phenotype | 7 (6.4) | 28 (4.0) | 35 (4.3) | 0.24 |
| Daptomycin MIC of >1 μg/ml | 3 (2.9) | 13 (2.0) | 16 (2.1) | 0.53 |
| Vancomycin MIC (μg/ml) | 0.78 | |||
| 0.5 | 1 (0.9) | 3 (0.4) | 4 (0.5) | |
| 0.75 | 7 (6.4) | 25 (3.6) | 32 (3.8) | |
| 1 | 19 (17.6) | 140 (19.9) | 159 (19.6) | |
| 1.5 | 54 (50.0) | 373 (52.9) | 427 (52.5) | |
| 2 | 26 (24.1) | 147 (20.9) | 173 (21.3) | |
| >2 | 2 (1.9) | 17 (2.4) | 19 (2.3) | |
| Polymicrobial infection | 12 (11.0) | 77 (10.9) | 89 (10.9) | 0.98 |
| agr group II | 50 (45.9) | 250 (35.5) | 300 (36.8) | 0.05 |
| PVL | 27 (24.8) | 224 (31.8) | 251 (30.8) | 0.14 |
| ACMEb | 30 (27.5) | 187 (28.4) | 217 (28.2) | 0.73 |
| USA300 clonec | 21 (19.3) | 169 (24.0) | 190 (23.3) | 0.28 |
a
No isolates were nonsusceptible to linezolid.
b
ACME was measured for all MRSA isolates and for methicillin-susceptible S. aureus isolates that were PVL positive and had spa type motif MBQBLO.
c
The USA300 clone was defined as MBQBLO spa motif positive, PVL positive, and ACME positive.